Tenxcloud (时速云): Founded in 2014, raised series C1
Tenxcloud is a container cloud Platform-as-a-Service (PaaS) provider focused on cloud native technology; providing customers with cloud storage, integrated software development and IT operations, microservices platform and other product services. This round was led by Beijing Huatai New Industry Investment Fund; final amount has yet to be disclosed.
CEO Huang Qigong said that this round of financing will mainly be used to increase investment in product R&D, market positioning, recruitment and build strategic cooperation with other companies.
Jing Data (鲸准): Founded in 2016, raised series B
Jing Data is a finance and technology service platform, focused on China's new economy. It has recently successfully RMB 100 million for its series B funding. This round was jointly led by Lanpu Capital Lanpu Capital and DYEE Capital, and joined by strategic investment by Zhangjiang Venture Capital.
Jing Data plans to utilise the recent investment to refine its data products, expand its coverage in the financial coverage, and develop its industrial innovation services to serve more regional governments with industrial upgrading needs.
Fenxiang Life (粉象生活): Founded in 2018, raised series A
Fenxiang Life, China's leading social e-commerce platform, announced that it had successfully raised tens of millions US dollar for its Series A financing. The round was led by Xiaomi and joined by DCM Ventures.
Sirnaomics (圣诺生物): Founded in 2004; raised series D
Sirnaomics is a bio-med startup that focuses on application of RNA interference (RNAi) technology in new drug creation. They have successfully raised USD 105 million for their Series D. Investors this round includes Walvax Biotechnology Co, Riverhead Capital and existing shareholder Rotating Boulder Fund. Funds raised will be used to further develop the proprietary RNAi drug, focusing on the treatment of cancer, fibrotic diseases, metabolic diseases and viral infections.
Sirnaomics has developed new drugs, utilising chemically synthesized RNAi triggers (short interfering RNA or siRNAs) delivered to target cells in vivo through patented peptide nanoparticles (PNP).
Dindang Kuaiyao (叮当快药): Founded in 2014; raised series B+
Dingdang Kuaiyao is an online-to-offline pharmacy that allows app users to purchase medicine and have it delivered to them. Investors include Taikang Life Insurance, Haier Biomedical, Dragon Gate Investment Partners, Softbank China and other state and corporate institutions.
According to founder Yang Wenleong, the RMB 1 billion raised will be used to expand the company in 10 more locations, covering all of China's first, second and third tier cities by 2021.
Xiaoyang Group (晓羊集团): Founded in 2016; raised series B+
Xiaoyang Group is a K-12 smart education platform that provides cloud services and Platform-As-A-Service (PaaS) solution for education institutes. It successfully closed its B+ round, raising more than RMB 60 million. Investors for this round include existing investors Yunqi Partners and Ameba Capital.
Xiaoyang Group markets its suite of services as 'three-in-one', encompassing a PaaS solution, a data centre and an application matrix connecting all the available services and products. Their PaaS solution is specially designed to manage course scheduling, optimise registration and provide open source tools and APIs for ease of adoption. The data centre helps schools achieve digitalisation of their stakeholder's data, profiling teachers, students, and classes. The application ecology is a multi-functional, smart education data-driven platform integrated with leading educational products.